Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 8/20 | 0.68 |
| ▸ | TTBK2 | Q6IQ55 | 8/20 | 0.68 |
| ▸ | TRPA1 | O75762 | 5/20 | 0.64 |
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | CSF1R | P07333 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30408294 | 0.82 | JAK2 (0.55) | TTBK1TTBK2TRPA1MEN1KMT2A | |
| SCHEMBL30123191 | 0.81 | TTBK1 (1.00) | TTBK1TTBK2 | |
| SCHEMBL2198300 | 0.80 | TRPA1 (0.68) | TTBK1TTBK2TRPA1TNNI3KMAPT | |
| SCHEMBL30564544 | 0.80 | TRPA1 (0.75) | TTBK1TTBK2TRPA1TNNI3KBRAF | |
| SCHEMBL2882091 | 0.80 | TRPA1 (0.75) | TTBK1TTBK2TRPA1TNNI3KBRAF | |
| SCHEMBL1893699 | 0.78 | TTBK1 (0.58) | TTBK1TTBK2TNNI3KBRAFKDR | |
| SCHEMBL29631643 | 0.78 | TTBK1 (0.58) | TTBK1TTBK2TNNI3KBRAFKDR | |
| SCHEMBL12999346 | 0.78 | TRPA1 (0.68) | TTBK1TTBK2TRPA1TNNI3KBRAF | |
| SCHEMBL4727429 | 0.75 | KMT2A (0.56) | TNNI3KBRAFKDRMAPK14MEN1 | |
| SCHEMBL29261085 | 0.75 | TRPA1 (0.66) | TTBK1TTBK2TRPA1TNNI3KBRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592433-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-11-26 | — | — | US | disclosed |
| US-20100324062-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-23 | — | — | US | disclosed |
| US-20100324062-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2010-12-23 | — | — | US | disclosed |
| EP-1940844-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2009-09-30 | — | — | EP | disclosed |
| EP-1940844-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM, LLC (BM) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007053343-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053343-A2 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324062-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | SYK, SRC, FYN | TTBK1 506/4885TTBK2 258/4885TRPA1 3264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.